NEW YORK (GenomeWeb) – T2 Biosystems announced after the close of the market Monday that it was backing away from earlier guidance on the number of commitments for its T2Candida sepsis panel expected in 2016 after a lower-than-expected number of customers adopted the test during the first quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.